Kala Bio, Inc. (KALA)
0.1901
0.00 (0.00%)
USD |
NASDAQ |
Oct 23, 16:00
0.192
0.00 (0.00%)
After-Hours: 20:00
Kala Bio Net Income (Quarterly) : -1.581M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.581M |
| March 31, 2026 | -1.621M |
| December 31, 2025 | 0.686M |
| September 30, 2025 | -7.564M |
| June 30, 2025 | -11.16M |
| March 31, 2025 | -8.947M |
| December 31, 2024 | -8.175M |
| September 30, 2024 | -8.95M |
| June 30, 2024 | -9.579M |
| March 31, 2024 | -11.81M |
| December 31, 2023 | -8.627M |
| September 30, 2023 | -8.704M |
| June 30, 2023 | -10.41M |
| March 31, 2023 | -14.46M |
| December 31, 2022 | -12.84M |
| September 30, 2022 | 29.07M |
| June 30, 2022 | -28.11M |
| March 31, 2022 | -32.94M |
| December 31, 2021 | -47.57M |
| September 30, 2021 | -28.13M |
| June 30, 2021 | -36.50M |
| March 31, 2021 | -30.41M |
| Date | Value |
|---|---|
| December 31, 2020 | -31.11M |
| September 30, 2020 | -27.95M |
| June 30, 2020 | -23.31M |
| March 31, 2020 | -21.96M |
| December 31, 2019 | -21.96M |
| September 30, 2019 | -23.18M |
| June 30, 2019 | -23.82M |
| March 31, 2019 | -25.39M |
| December 31, 2018 | -25.22M |
| September 30, 2018 | -15.60M |
| June 30, 2018 | -14.62M |
| March 31, 2018 | -11.30M |
| December 31, 2017 | -11.29M |
| September 30, 2017 | -10.18M |
| June 30, 2017 | -10.99M |
| March 31, 2017 | -9.759M |
| June 30, 2016 | -9.853M |
| March 31, 2016 | -5.252M |
| December 31, 2015 | -4.915M |
| September 30, 2015 | -4.672M |
| December 31, 2014 | -5.148M |
| September 30, 2014 | -5.174M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 1.581M |
| EPS Diluted (Quarterly) | -21.32 |
| Enterprise Value | -3.552M |
| Earnings Yield | -38.89K% |
| Normalized Earnings Yield | -51664.39 |